Immunotherapy [18,47,74,75,76] harnesses immune response activation in the tumor microenvironment to target and destroy cancer cells using checkpoint inhibitors [69], such as those targeting programmed cell death protein-1 (PD-1) and its ligand (PD-L1). This evidence concerns the gene CD274 and neoplasm.